Insight

Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?

Photo from Erman Akkus/X

Jul 25, 2024, 14:02

Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?

Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on X:

“Should up-front SRS be added to TKI in brain metastatic EGFR/ALK+ NSCLC?

Improves time-to-CNS progression HR: 0.63 (0.42 to 0.96), P = .033
No difference in OS
More than 20% of patients had >11 brain metastases.”

Source: Erman Akkus/X

Erman Akkus

Authors: Luke R.G. Pike, Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall, Erqi L. Pollom, Caressa Hui, Vera Qu, Jacob Langston, Veronica Chiang, Michael Grant, Sarah B. Goldberg, Joshua D. Palmer, Rahul N. Prasad, Tony J.C. Wang, Albert Lee, Catherine A. Shu, Lanyi Nora Chen, Nicholas J. Thomas, Steve E. Braunstein, Brian D. Kavanagh, D. Ross Camidge, Chad G. Rusthoven

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Albert Lee ALK Brandon S. Imber Brian D. Kavanagh cancer Caressa Hui Catherine A. Shu Chad G. Rusthoven D. Ross Camidge EGFR Emily Miao Erman Akkus Erqi L. Pollom Jacob Langston Joshua D. Palmer Journal of Clinical Oncology Lanyi Nora Chen Lillian A. Boe Luke R. G. Pike Michael Grant Nathaniel J. Myall Nicholas J. Thomas NSCLC OncoDaily Oncology Rahul N. Prasad Sarah B. Goldberg Steve E. Braunstein Tejas Patil Tony J.C. Wang Vera Qu Veronica Chiang

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage